©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 18, 2023; 13(4): 129-137
Published online Jun 18, 2023. doi: 10.5500/wjt.v13.i4.129
Published online Jun 18, 2023. doi: 10.5500/wjt.v13.i4.129
Women’s health issues in solid organ transplantation: Breast and gynecologic cancers in the post-transplant population
Michelle Jones-Pauley, Department of Gastroenterology, Houston Methodist Hospital, Houston, TX 77008, United States
Sudha Kodali, Tamneet Basra, David W Victor, Department of Transplant Hepatology, Houston Methodist Hospital, Houston, TX 77030, United States
Author contributions: Jones-Pauley M, Kodali S, Basra T, and Victor DW wrote the manuscript; All authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Corresponding author: David W Victor, MD, Director, Department of Transplant Hepatology, Houston Methodist Hospital, 6550 Fannin St, Houston, TX 77030, United States.
Received: December 29, 2022
Peer-review started: December 29, 2022
First decision: March 1, 2023
Revised: April 19, 2023
Accepted: May 31, 2023
Article in press: May 31, 2023
Published online: June 18, 2023
Processing time: 168 Days and 17.2 Hours
Peer-review started: December 29, 2022
First decision: March 1, 2023
Revised: April 19, 2023
Accepted: May 31, 2023
Article in press: May 31, 2023
Published online: June 18, 2023
Processing time: 168 Days and 17.2 Hours
Core Tip
Core Tip: Survival after solid organ transplant is continually improving. Because of this, patients are living longer and are requiring long-term monitoring for malignancies. There is growing evidence that breast and gynecologic cancers (specifically cervical and vulvovaginal cancers) may have a higher mortality rate in post-transplant patients. Despite this increased mortality risk, there is currently no consistent standard among transplant societies for screening and identifying these cancers in post-transplant patients. Ultimately, data are not robust and further studies are needed to determine if more aggressive screening strategies would be of benefit for these cancers.